Sarepta Therapeutics (SRPT) Cost of Revenue (2017 - 2026)

Sarepta Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $108.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 20.93% year-over-year to $108.8 million in Q1 2026; TTM through Mar 2026 was $810.8 million, a 99.66% increase from a year earlier, with the FY2025 full-year figure at $839.6 million, up 163.12% from the prior year.
• Cost of Revenue fell to $108.8 million in Q1 2026 per SRPT's latest filing, from $398.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $398.7 million in Q4 2025 and bottomed at $30.8 million in Q4 2022.
• The 5-year median for Cost of Revenue is $44.5 million (2024), against an average of $91.6 million.
• Across the five-year window, Cost of Revenue soared 242.48% in 2025 and fell 20.93% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $30.8 million in 2022, then soared by 43.43% to $44.2 million in 2023, then soared by 199.49% to $132.3 million in 2024, then jumped by 201.36% to $398.7 million in 2025, then sank by 72.72% to $108.8 million in 2026.
• Per Business Quant, the three latest SRPT Cost of Revenue figures stand at $108.8 million (Q1 2026), $398.7 million (Q4 2025), and $150.8 million (Q3 2025).